Investigational drug · Phase 3
TAR-200
Also called: JNJ-17000139, Gemcitabine-Releasing Intravesical System
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
10
Any phase or sponsor naming "TAR-200"
First trial start
2020
Dec 7, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAR-200", any sponsor or status.
Conditions studied
As listed on its trial records.
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TAR-200" as an intervention, largest first.
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05714202 · 1,135 participants · Start Mar 23, 2023 · Primary completion Sep 18, 2029
Drug: TAR-200; Cetrelimab and 1 more · For: Bladder Cancer
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Long Beach, California · 240 sites in all
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04658862 · 518 participants · Start Dec 7, 2020 · Primary completion Dec 30, 2026
Drug: Cetrelimab; TAR-200 and 2 more · For: Urinary Bladder Neoplasms
Sites: Loma Linda, California; Los Angeles, California; Santa Monica, California · 290 sites in all
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06211764 · 272 participants · Start Apr 9, 2024 · Primary completion Nov 27, 2030
Drug: TAR-200; Mitomycin C and 1 more · For: Non-Muscle Invasive Bladder Neoplasms
Sites: Little Rock, Arkansas; Los Alamitos, California; Los Angeles, California · 123 sites in all
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04640623 · 220 participants · Start Dec 18, 2020 · Primary completion Jul 3, 2025
Drug: TAR-200; Cetrelimab · For: Urinary Bladder Neoplasms
Sites: Tucson, Arizona; Los Angeles, California; Sherman Oaks, California · 144 sites in all
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04919512 · 163 participants · Start Jul 7, 2022 · Primary completion Feb 4, 2025
Drug: TAR-200; Cetrelimab · For: Urinary Bladder Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 109 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03404791 · 35 participants · Start Nov 20, 2017 · Primary completion Dec 23, 2019
Drug: TAR-200 · For: Urinary Bladder Neoplasms
Sites: Phoenix, Arizona; Dalton, Georgia; Hanover, Maryland · 12 sites in all
Taris Biomedical LLCIndustry
NCT02722538 · 23 participants · Start May 31, 2016 · Primary completion May 2, 2019
Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 · For: Urinary Bladder Cancer
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland · 6 sites in all
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminated
Taris Biomedical LLCIndustry
NCT03518320 · 13 participants · Start Jan 2, 2019 · Primary completion Dec 11, 2019
Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200; Nivolumab Injection [Opdivo] · For: Bladder Cancer TNM Staging Primary Tumor (T) T2; Bladder Cancer TNM Staging Primary Tumor (T) T2A; Bladder Cancer TNM Staging Primary Tumor (T) T2B and 6 more
Sites: Hinsdale, Illinois; Rochester, New York; Durham, North Carolina · 6 sites in all
Taris Biomedical LLCIndustry
NCT02720367 · 12 participants · Start Jan 2016 · Primary completion Jan 2018
Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 · For: Urinary Bladder Cancer
Sites: Nijmegen, Netherlands · 2 sites in all
- Pre-Approval Expanded Access Study for TAR-200 Treating Physician UseApproved for marketing
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06877676
Drug: TAR-200 · For: Non-Muscle Invasive Bladder Neoplasms
Newest research
PubMed records naming it or its code names, newest first.
- Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
Williams S, Cho S, Morrison L, et al. · J Med Econ 2026
- Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.
Yang M, Chai X, Ye D, et al. · J Med Econ 2026
- Comparison of novel salvage therapies for BCG-unresponsive NMIBC against gemcitabine/docetaxel: A reconstructed individual patient data analysis.
Almohtasib J, Kaul S, Perez-Londono A, et al. · Urol Oncol 2026
- Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response.
Chen C, Xie B, Chen C, et al. · Front Immunol 2026
- Bladder-Sparing Therapies for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ: An Upper and a Lower Response Group With an Unstable Boundary.
Kasahara R · Cureus 2026
- Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
Fukushima H, Yoshida S, Yajima S, et al. · Anticancer Res 2026
Also in development for Urinary Bladder Neoplasms
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VepugratinibLY3866288Phase 32 trials
Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- MK-3120SKB410Phase 24 trials
Merck & Co. · Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.